255 related articles for article (PubMed ID: 34130525)
21. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
22. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
Scuteri D; Tonin P; Nicotera P; Vulnera M; Altieri GC; Tarsitano A; Bagetta G; Corasaniti MT
Toxins (Basel); 2022 Aug; 14(8):. PubMed ID: 36006191
[TBL] [Abstract][Full Text] [Related]
23. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Hong P; Wu X; Liu Y
Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
[TBL] [Abstract][Full Text] [Related]
24. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
Ailani J; Blumenfeld AM
Headache; 2022 Jan; 62(1):106-108. PubMed ID: 34877663
[No Abstract] [Full Text] [Related]
25. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
27. Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
Bruloy E; Sinna R; Grolleau JL; Bout-Roumazeilles A; Berard E; Chaput B
Plast Reconstr Surg; 2019 Jan; 143(1):239-250. PubMed ID: 30589800
[TBL] [Abstract][Full Text] [Related]
28. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
Rothrock JF; Adams AM; Lipton RB; Silberstein SD; Jo E; Zhao X; Blumenfeld AM;
Headache; 2019 Nov; 59(10):1700-1713. PubMed ID: 31559634
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis.
Forbes RB; McCarron M; Cardwell CR
Headache; 2020 Sep; 60(8):1542-1557. PubMed ID: 32668023
[TBL] [Abstract][Full Text] [Related]
30. CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis.
Han L; Liu Y; Xiong H; Hong P
Brain Behav; 2019 Feb; 9(2):e01215. PubMed ID: 30656853
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of pharmacological prophylaxis for chronic migraine: a systematic review and network meta-analysis.
Zhao C; Li C; Yu X; Dai X; Zou W
J Neurol; 2024 Jun; ():. PubMed ID: 38910144
[TBL] [Abstract][Full Text] [Related]
32. [Chronic and Refractory Migraine: How to Diagnose and Treat].
Parreira E; Luzeiro I; Pereira Monteiro JM
Acta Med Port; 2020 Nov; 33(11):753-760. PubMed ID: 33160424
[TBL] [Abstract][Full Text] [Related]
33. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
Mathew NT; Jaffri SF
Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
[TBL] [Abstract][Full Text] [Related]
34. Impact of the botulinum-A toxin on prevention of adult migraine disorders.
Shen B; Wang L
J Integr Neurosci; 2020 Mar; 19(1):201-208. PubMed ID: 32259898
[TBL] [Abstract][Full Text] [Related]
35. Treatment of chronic migraine.
Diener HC; Holle D; Dodick D
Curr Pain Headache Rep; 2011 Feb; 15(1):64-9. PubMed ID: 21080112
[TBL] [Abstract][Full Text] [Related]
36. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.
Israel H; Neeb L; Reuter U
Curr Pain Headache Rep; 2018 Apr; 22(5):38. PubMed ID: 29623520
[TBL] [Abstract][Full Text] [Related]
37. Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy.
Scuteri D; Corasaniti MT; Tonin P; Nicotera P; Bagetta G
J Headache Pain; 2021 Jul; 22(1):87. PubMed ID: 34330208
[TBL] [Abstract][Full Text] [Related]
38. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
[TBL] [Abstract][Full Text] [Related]
39. Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.
Ferrari MD; Zuurbier KWM; Barash S; Ning X; Cohen JM
Headache; 2022 Apr; 62(4):530-533. PubMed ID: 35383922
[No Abstract] [Full Text] [Related]
40. Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine.
Kouremenos E; Arvaniti C; Constantinidis TS; Giannouli E; Fakas N; Kalamatas T; Kararizou E; Naoumis D; Mitsikostas DD;
J Headache Pain; 2019 Dec; 20(1):113. PubMed ID: 31835997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
